Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17574414rdf:typepubmed:Citationlld:pubmed
pubmed-article:17574414lifeskim:mentionsumls-concept:C0166417lld:lifeskim
pubmed-article:17574414lifeskim:mentionsumls-concept:C0001128lld:lifeskim
pubmed-article:17574414lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:17574414lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:17574414lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:17574414lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:17574414pubmed:issue16lld:pubmed
pubmed-article:17574414pubmed:dateCreated2007-7-30lld:pubmed
pubmed-article:17574414pubmed:abstractTextThe design and synthesis of novel series of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid (pyrimidone) derivatives that are high affinity ligands for peroxisome proliferators activated receptor gamma have been reported as a potential substitute of 2,4-thiazolidinedione head group. The FlexX docking and radioligand binding affinity of some promising compounds of this series is comparable to that of thiazolidinedione based antidiabetic drugs currently in clinical use.lld:pubmed
pubmed-article:17574414pubmed:languageenglld:pubmed
pubmed-article:17574414pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17574414pubmed:citationSubsetIMlld:pubmed
pubmed-article:17574414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17574414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17574414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17574414pubmed:statusMEDLINElld:pubmed
pubmed-article:17574414pubmed:monthAuglld:pubmed
pubmed-article:17574414pubmed:issn0960-894Xlld:pubmed
pubmed-article:17574414pubmed:authorpubmed-author:KumarRakeshRlld:pubmed
pubmed-article:17574414pubmed:authorpubmed-author:RamachandranU...lld:pubmed
pubmed-article:17574414pubmed:authorpubmed-author:MittalAmitAlld:pubmed
pubmed-article:17574414pubmed:issnTypePrintlld:pubmed
pubmed-article:17574414pubmed:day15lld:pubmed
pubmed-article:17574414pubmed:volume17lld:pubmed
pubmed-article:17574414pubmed:ownerNLMlld:pubmed
pubmed-article:17574414pubmed:authorsCompleteYlld:pubmed
pubmed-article:17574414pubmed:pagination4613-8lld:pubmed
pubmed-article:17574414pubmed:meshHeadingpubmed-meshheading:17574414...lld:pubmed
pubmed-article:17574414pubmed:meshHeadingpubmed-meshheading:17574414...lld:pubmed
pubmed-article:17574414pubmed:meshHeadingpubmed-meshheading:17574414...lld:pubmed
pubmed-article:17574414pubmed:meshHeadingpubmed-meshheading:17574414...lld:pubmed
pubmed-article:17574414pubmed:meshHeadingpubmed-meshheading:17574414...lld:pubmed
pubmed-article:17574414pubmed:meshHeadingpubmed-meshheading:17574414...lld:pubmed
pubmed-article:17574414pubmed:meshHeadingpubmed-meshheading:17574414...lld:pubmed
pubmed-article:17574414pubmed:meshHeadingpubmed-meshheading:17574414...lld:pubmed
pubmed-article:17574414pubmed:year2007lld:pubmed
pubmed-article:17574414pubmed:articleTitleDesign and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators.lld:pubmed
pubmed-article:17574414pubmed:affiliationDepartment of Pharmaceutical Technology, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab 160 062, India. rakvats@gmail.comlld:pubmed
pubmed-article:17574414pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17574414pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:17574414lld:chembl